ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point
Executive Summary
The generics industry does not appear satisfied with an FDA proposal to treat all applications equally under a new generic drug user fee program, preferring instead to create another, separate user fee that would clear the ANDA application backlog faster.
You may also be interested in...
GDUFA Launch Pains: Facility List Fluctuations, Back-Due Backlog Fees
FDA still has backlog fees in arrears more than two months past the payment deadline, but cannot forcibly withdraw the applications; facility listings also change consistently because industry can update them as needed.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
As GDUFA Launch Nears, Is Sitting In The Backlog More Appealing?
More submissions are going into the generic drug backlog, likely because the backlog fee is expected to be less than half the GDUFA application fee.